Cancer Hospital Chinese Academy Of Medical Science, Shenzhen Center

This is an early safety study testing a personalized mRNA vaccine called RH125 for people with advanced solid tumors that have not responded to standard treatments. The study will enroll up to 36 participants to see if the vaccine, given alone or with an immunotherapy drug, is sa…